Answers are grounded in this paper and cite their sources.
The use of [ 18 F]-2-fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) imaging is emerging as an important tool in the treatment of esophageal cancer. Over a decade ago, the MUNICON investigators first incorporated metabolic assessment by PET into clinical trial design and evaluated the strategy of taking patients with locally advanced gastroesophageal junction (GEJ) adenocarcinomas, who had a suboptimal response to two weeks of induction chemotherapy with 5-fluorouracil (FU)/cisplatin directly to surgery (1).
No takes yet. Share an insight, caveat, or question.
Greally et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: